ReviewBioMed research international2013
Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview.Advances in therapy · 2019Pooled it
- The Supportive Role of Plant-Based Substances in AMD Treatment and Their Potential.International journal of molecular sciences · 2025Review
- Human Umbilical Tissue-Derived Cells Secrete Soluble VEGFR1 and Inhibit Choroidal Neovascularization.Molecular therapy. Methods & clinical development · 2019Article
- MicroRNA-145 Regulates Pathological Retinal Angiogenesis by Suppression of TMOD3.Molecular therapy. Nucleic acids · 2019Article
- CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration.Nature communications · 2018Article
- Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGFMarine drugs · 2018Article
- Microfluidic methods for aptamer selection and characterization.The Analyst · 2017Review
- Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.Molecular therapy. Nucleic acids · 2017Review
- Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab.BMC ophthalmology · 2017Observational
- Ferrochelatase is a therapeutic target for ocular neovascularization.EMBO molecular medicine · 2017Article
- Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids.Molecular therapy. Nucleic acids · 2017Article
- Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.Clinical ophthalmology (Auckland, N.Z.) · 2015Review
- Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach.Frontiers in pharmacology · 2015Article
- Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain.BMC ophthalmology · 2014Observational
- Emodin-loaded magnesium silicate hollow nanocarriers for anti-angiogenesis treatment through inhibiting VEGF.International journal of molecular sciences · 2014Article
- Tight junction modulation of the blood brain barrier: CNS delivery of small molecules.Tissue barriersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.